Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795022 · ClinicalTrials.gov registry record · Phase 1
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
A Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT06795022: Recruiting Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
NCT06795022 is a Phase 1 study of Hepatocellular Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 304 participants, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06795022, a Phase 1 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Conditions Studied
Interventions
- DRUG AZD9793 Intravenous (IV) monotherapy
- DRUG AZD9793 Subcutaneous (SC) monotherapy)
Study Locations (20)
Other
- Research Site - Chengdu
- Research Site - Guangzhou
- Research Site - Harbin
- Research Site - Shanghai
- Research Site - Pokfulam
- Research Site - Shatin
- Research Site - Kashiwa
- Research Site - Yokohama
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Pamplona
- Research Site - Taipei
- Research Site - Taoyuan District
California
- Research Site - La Jolla
- Research Site - Los Angeles
Maryland
- Research Site - Baltimore
Missouri
- Research Site - St Louis
New Jersey
- Research Site - Hackensack
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2028-07-25 |
| Phase | Phase 1 |
What NCT06795022 shows while recruiting
NCT06795022 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which AZD9793 Intravenous (IV) monotherapy is the first listed.
NCT06795022 names 20 study sites across 6 states, led by Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06795022 about?
NCT06795022 is a clinical study titled "First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours". This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
What is the current status of trial NCT06795022?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 304 participants. The study started on 2025-03-27. Estimated completion is 2028-07-25.
What conditions does trial NCT06795022 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06795022?
The interventions under investigation include: AZD9793 Intravenous (IV) monotherapy (DRUG), AZD9793 Subcutaneous (SC) monotherapy) (DRUG).
Who is sponsoring clinical trial NCT06795022?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795022 being conducted?
This trial has 20 study locations across California, Maryland, Missouri, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06795022's enrollment target sits among peer trials
304 36th of 145 higher than 110 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI